Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:KRYS NYSE:OGN NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$3.56+15.6%$2.59$7.96▼$24.15$17.95M0.6315,685 shs328,619 shsKRYSKrystal Biotech$147.70-2.0%$145.83$122.80▼$207.84$4.36B0.7409,475 shs257,853 shsOGNOrganon & Co.$9.40+2.3%$9.61$8.01▼$22.67$2.39B0.64.77 million shs4.58 million shsVRNAVerona Pharma PLC American Depositary Share$105.91+0.0%$102.25$24.50▼$105.98$9.16B0.121.44 million shs712,567 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+15.58%+44.72%+32.34%+22.76%-79.63%KRYSKrystal Biotech-2.03%-1.85%-3.60%+16.24%-27.57%OGNOrganon & Co.+2.40%-0.27%-6.61%+2.12%-58.19%VRNAVerona Pharma PLC American Depositary Share+0.03%+0.33%+0.73%+31.03%+293.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech4.768 of 5 stars3.41.00.04.72.63.33.1OGNOrganon & Co.4.7615 of 5 stars3.32.01.73.73.11.73.1VRNAVerona Pharma PLC American Depositary Share2.4335 of 5 stars2.15.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AKRYSKrystal Biotech 2.88Moderate Buy$210.3842.43% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0091.59% UpsideVRNAVerona Pharma PLC American Depositary Share 2.14Hold$109.002.92% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, KRYS, VRNA, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.008/8/2025VRNAVerona Pharma PLC American Depositary ShareZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/5/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$176.00 ➝ $166.008/5/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.007/25/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.007/25/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.007/22/2025KRYSKrystal BiotechBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$193.00 ➝ $192.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/10/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AKRYSKrystal Biotech$290.52M14.71$4.54 per share32.51$35.96 per share4.11OGNOrganon & Co.$6.40B0.38$5.05 per share1.86$2.82 per share3.33VRNAVerona Pharma PLC American Depositary Share$42.28M216.68N/AN/A$3.22 per share32.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9230.0214.65N/A40.85%15.21%13.81%11/3/2025 (Estimated)OGNOrganon & Co.$864M$2.693.492.510.8411.15%163.88%6.99%10/30/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,530.33N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest ALVR, KRYS, VRNA, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.85%N/A2.97%N/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ALatest ALVR, KRYS, VRNA, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78KRYSKrystal BiotechN/A9.689.33OGNOrganon & Co.11.981.651.13VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%KRYSKrystal Biotech86.29%OGNOrganon & Co.77.43%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%KRYSKrystal Biotech13.70%OGNOrganon & Co.1.96%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableOGNOrganon & Co.4,000259.97 million254.87 millionNot OptionableVRNAVerona Pharma PLC American Depositary Share3086.50 million82.34 millionOptionableALVR, KRYS, VRNA, and OGN HeadlinesRecent News About These CompaniesHere’s How Wall Street is Reacting to Verona Pharma (VRNA)’s AcquisitionAugust 28 at 12:55 AM | finance.yahoo.comAffinity Asset Advisors LLC Reduces Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 28 at 9:02 AM | marketbeat.comPrice T Rowe Associates Inc. MD Has $118.49 Million Stock Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 27 at 5:04 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives $109.00 Average Target Price from AnalystsAugust 27 at 2:55 AM | americanbankingnews.comAmerican Century Companies Inc. Sells 310,985 Shares of Verona Pharma PLC American Depositary Share $VRNAAugust 26, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Recommendation of "Hold" by BrokeragesAugust 26, 2025 | marketbeat.com10,635 Shares in Verona Pharma PLC American Depositary Share $VRNA Purchased by Jasper Ridge Partners L.P.August 25, 2025 | marketbeat.com87,402 Shares in Verona Pharma PLC American Depositary Share $VRNA Acquired by Russell Investments Group Ltd.August 24, 2025 | marketbeat.comAtika Capital Management LLC Cuts Stock Position in Verona Pharma PLC American Depositary Share $VRNAAugust 23, 2025 | marketbeat.comCandriam S.C.A. Reduces Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 23, 2025 | marketbeat.comWellington Management Group LLP Has $135.33 Million Stock Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 23, 2025 | marketbeat.comShort Interest in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Declines By 39.2%August 21, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 12-Month High - Should You Buy?August 20, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Short Interest Down 39.2% in JulyAugust 20, 2025 | americanbankingnews.comTokio Marine Asset Management Co. Ltd. Makes New $698,000 Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 18, 2025 | marketbeat.comLPL Financial LLC Purchases 20,500 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 18, 2025 | marketbeat.comLord Abbett & CO. LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 17, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Holdings Trimmed by Aisling Capital Management LPAugust 16, 2025 | marketbeat.comVirtu Financial LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 14, 2025 | marketbeat.comAigen Investment Management LP Purchases New Shares in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 13, 2025 | marketbeat.comAll You Need to Know About Verona Pharma (VRNA) Rating Upgrade to BuyAugust 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, KRYS, VRNA, and OGN Company DescriptionsAlloVir NASDAQ:ALVR$3.56 +0.48 (+15.58%) As of 08/28/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Krystal Biotech NASDAQ:KRYS$147.70 -3.06 (-2.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$149.26 +1.56 (+1.06%) As of 08/29/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Organon & Co. NYSE:OGN$9.40 +0.22 (+2.34%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$9.43 +0.03 (+0.32%) As of 08/29/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$105.91 +0.03 (+0.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$105.90 -0.01 (-0.01%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
